Scilex Holding Co SCLX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-01-11 |
| Shares Out. | 8,490,000 |
| Website | scilexholding.com/ ↗ |
| Phone | 13026365401 |
| Employees | 34 |
| Revenue | $8.6M |
| Gross Profit | $4.2M |
| Net Income | -$45.7M |
| Free Cash Flow | -$3.4M |
| Total Assets | $293.6M |
| Total Liabilities | $547.7M |
| Equity | -$254.1M |
About Scilex Holding Co
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Scilex Holding Co is a publicly traded company under the ticker symbol SCLX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)